PFND vs REGN: Which Stock is Better?

Side-by-side comparison of Pathfinder Cell Therapy Inc and Regeneron Pharmaceuticals Inc in 2026

Comparison Updated:

PFND

Pathfinder Cell Therapy Inc

$0.00

REGN

Regeneron Pharmaceuticals Inc

$749.41

Key Metrics Comparison

MetricPFNDREGNWinner
Market Cap$0.07M$79.35BREGN
P/E RatioN/A18.08REGN
EPS (TTM)$N/A$41.51REGN
Revenue Growth0.0%0.0%REGN
Gross Margin0.0%44.6%REGN

Analyze PFND

Full quant analysis

Analyze REGN

Full quant analysis

Analyze Each Stock

Frequently Asked Questions

Is PFND or REGN a better investment?

Comparing PFND and REGN: Pathfinder Cell Therapy Inc has a market cap of $0.07M while Regeneron Pharmaceuticals Inc has $79.35B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.

What is the difference between PFND and REGN?

PFND (Pathfinder Cell Therapy Inc) and REGN (Regeneron Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.

Which stock has better value: PFND or REGN?

Based on P/E ratios, compare detailed valuation metrics on our dashboard.

Which is growing faster: PFND or REGN?

REGN has higher revenue growth at 0.0% vs 0.0% for PFND.

Which company is more profitable: PFND or REGN?

Regeneron Pharmaceuticals Inc (REGN) has higher gross margins at 44.6% compared to 0.0% for PFND.

Which is the larger company: PFND or REGN?

Regeneron Pharmaceuticals Inc (REGN) is larger with a market cap of $79.35B compared to $0.07M for PFND.

Should I buy PFND or REGN in 2026?

Both PFND and REGN have investment merit. PFND trades at $0.00 while REGN trades at $749.41. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.

What are the key differences between PFND and REGN stock?

Key differences: Market Cap ($0.07M vs $79.35B), P/E Ratio (N/A vs 18.1x), Revenue Growth (0.0% vs 0.0%), Gross Margin (0.0% vs 44.6%).

Popular Stock Comparisons